Nexus Pharmaceuticals v. Gland Pharma: Ephedrine Patent Dispute Settled After 444 Days
Nexus Pharmaceuticals filed suit against Indian generics manufacturer Gland Pharma in the District of New Jersey, asserting four patents covering ephedrine and ephedrine salt compositions. The case resolved by settlement after 444 days, with the court administratively terminating the action and ordering dismissal with prejudice absent final papers within 60 days.
Four-Patent Ephedrine Dispute Ends in Settlement Before Trial
On April 10, 2023, Nexus Pharmaceuticals, Inc. filed an infringement action against Gland Pharma, Ltd. in the U.S. District Court for the District of New Jersey (Case No. 1:23-cv-02032). The complaint asserted four patents — US11426369B2, US11241400B2, US11478436B2, and US11090278B2 — all directed to compositions comprising ephedrine or an ephedrine salt and methods of making and using the same. Gland Pharma, a major Indian injectable pharmaceuticals manufacturer, was the named defendant.
The action concluded on June 27, 2024, when the court entered an administrative termination order following notice that the parties had settled. The order does not constitute a dismissal under the Federal Rules of Civil Procedure; instead, it required the parties to file formal dismissal papers within 60 days. Absent those papers or a request to reopen, the court indicated it would dismiss the action with prejudice and without costs — a standard NJ District settlement-management procedure.
The 444-day duration suggests the parties engaged in substantive litigation activity — likely including early claim construction skirmishes and discovery — before reaching resolution. The terms of the settlement are not disclosed in the public record. The administrative termination structure, rather than an immediate Rule 41 stipulation, is consistent with parties needing additional time to finalise licensing or supply terms before formalising dismissal.
Filing to Case Settled in 444 days
444 days — above the median for NJ District pharmaceutical patent disputes
Case settled: what the administrative termination order means for both parties
Administrative termination is not a dismissal — yet
The court’s June 27, 2024 order explicitly states it does not constitute a dismissal under the Federal Rules of Civil Procedure. This is a procedural holding pattern used in the District of New Jersey: the case is suspended while parties finalise settlement documents. If formal dismissal papers are not filed within 60 days, the court will dismiss with prejudice and without costs automatically — effectively locking in a defendant-favourable cost structure.
NJ administrative settlement procedureWith prejudice vs. without prejudice: what the public record says
The order specifies that the court’s automatic dismissal — if triggered — would be with prejudice and without costs. However, the parties may file their own stipulated dismissal on different terms. The public record does not disclose whether the parties ultimately filed a voluntary dismissal with or without prejudice, or what conditions were attached. Practitioners should not assume the case ended with prejudice solely based on the administrative order’s fallback mechanism.
Prejudice terms not publicly confirmedNexus secures settlement before trial on four ephedrine patents
For Nexus Pharmaceuticals, settlement before trial avoids the risk of an adverse claim construction ruling that could have narrowed or invalidated its ephedrine patent portfolio. Settlement also enables confidential licensing or supply restrictions that a court judgment could not provide. All four patents remain in force and unadjudicated on the merits, preserving Nexus’s ability to assert them against other parties.
Patents survive — merits unadjudicatedGland Pharma avoids an injunction and public invalidity record
Settlement allows Gland Pharma to avoid a potentially precedent-setting infringement or validity ruling on the four Nexus ephedrine patents. No public finding of infringement was made. Depending on undisclosed terms, Gland may have obtained a licence, supply agreement, or market entry date. The absence of a costs award is consistent with a negotiated resolution rather than a defendant win on the merits.
No infringement finding — terms undisclosedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Nexus Pharmaceuticals, Inc. | Company | Specialty pharmaceutical company — holder of US11426369B2 and three further ephedrine patentsSearch in Eureka ↗ |
| Defendant | Gland Pharma, Ltd. | Company | Gland Pharma, Ltd. — Indian injectable generics manufacturer and ANDA filerSearch in Eureka ↗ |
| Plaintiff counsel | Rebekah R. Conroy | Attorney | Counsel for Nexus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Stone Conroy LLC | Law Firm | Representing Nexus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Amlan Ray | Attorney | Counsel for Gland Pharma, Ltd.Search in Eureka ↗ |
| Defendant law firm | Windels Marx Lane And Mittendorf, LLP | Law Firm | Representing Gland Pharma, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The administrative termination order reflects a settlement reached before any merits adjudication. No finding of infringement, validity, or claim scope was made by the court. The order’s language — specifying a 60-day window and a fallback dismissal with prejudice and without costs — is procedurally standard in the District of New Jersey and does not itself determine the substantive outcome. The commercially significant terms, including any licensing royalties, authorised generic provisions, or market-entry timelines, remain confidential and cannot be inferred from the public docket.
US11426369B2 — Ephedrine salt compositions for injectable pharmaceutical use
The four asserted patents — US11426369B2, US11241400B2, US11478436B2, and US11090278B2 — all relate to compositions comprising ephedrine or an ephedrine salt and methods of making and using the same. Ephedrine is a sympathomimetic agent widely used intravenously to manage hypotension during anaesthesia, particularly spinal anaesthesia for caesarean delivery. The application dates (spanning US16/876020 through US17/738557) suggest a continuation or continuation-in-part family, meaning the patents likely share a common specification and build incrementally on earlier claim scope.
A four-patent family in this space signals that Nexus is pursuing broad and layered protection around its ephedrine product line — a strategy designed to complicate generic entry by requiring challengers to design around or invalidate multiple claims simultaneously. For competitors, the overlapping scope of a continuation family means that designing around one patent may not clear the entire portfolio. The assertion against Gland Pharma, a major injectable generics manufacturer, suggests this portfolio is actively managed and commercially significant in the US hospital market.
Should you run an FTO against the Nexus ephedrine patent family?
Any company developing, manufacturing, or seeking ANDA approval for injectable ephedrine or ephedrine salt products intended for the US market should treat these four patents as active barriers. The continuation family structure means claim scope may differ meaningfully across patents, requiring independent analysis of each. Companies with existing ephedrine injectable products should also review whether post-grant amendments have affected claim breadth before relying on earlier FTO opinions.
PatSnap Eureka’s FTO Search Agent can map all four Nexus ephedrine patents against your formulation, identify prosecution history estoppel, surface related continuations not yet asserted, and flag co-pending applications that could generate additional family members. For R&D teams in the injectable anaesthesia or vasopressor space, this is an essential pre-filing screen — particularly given Nexus’s demonstrated willingness to litigate all four patents simultaneously.
Run a freedom-to-operate analysis on US11426369B2 to assess your product’s exposure
Run FTO in Eureka →Similar pharmaceutical patent infringement cases in NJ District Court
Explore comparable injectable pharmaceutical patent assertions and settlement patterns in the District of New Jersey, the primary venue for US pharma IP disputes.
What this case signals for the injectable pharmaceuticals IP landscape
A four-patent ephedrine portfolio assertion ending in settlement highlights how branded injectable firms are aggressively using layered patent strategies to manage generic entry.
Layered patent portfolios increase settlement leverage in pharma disputes
Nexus asserted four distinct patents covering ephedrine compositions and methods. Multi-patent assertions raise the cost and complexity of litigation for generic challengers, often making settlement economically rational before claim construction. Competitors in the injectable anaesthesia space should audit their own product compositions against each of the four Nexus patents independently.
NJ District administrative termination orders preserve plaintiff optionality
The District of New Jersey’s administrative termination procedure — as used here — gives patent holders a 60-day window to convert a settlement in principle into binding dismissal terms. This structure benefits plaintiffs who need time to finalise licensing royalty rates or market exclusivity windows before committing to a Rule 41 stipulation.
Nexus v Gland — key questions answered
Nexus asserted four patents: US11426369B2, US11241400B2, US11478436B2, and US11090278B2. All four cover compositions comprising ephedrine or an ephedrine salt and methods of making and using the same, consistent with a continuation patent family directed to injectable ephedrine pharmaceutical products.
The case settled. On June 27, 2024, the District of New Jersey entered an administrative termination order after the parties reported settlement. The order is not a dismissal under the Federal Rules; it gave the parties 60 days to file formal dismissal papers. The substantive settlement terms are not publicly disclosed.
Administrative termination in the District of New Jersey is a procedural tool that suspends the case while parties finalise settlement documents. It is not a Rule 41 dismissal. If the parties do not file dismissal papers or request reopening within 60 days, the court will dismiss with prejudice and without costs. It preserves flexibility for parties negotiating complex licensing or supply terms.
Yes. Because the case settled without any court ruling on validity or infringement, all four patents — US11426369B2, US11241400B2, US11478436B2, and US11090278B2 — remain legally in force and unadjudicated on the merits. They can still be asserted against other parties developing injectable ephedrine products.
The case signals that Nexus is actively enforcing a layered continuation patent family around injectable ephedrine compositions in the US market. Gland Pharma’s involvement suggests a potential ANDA or generic product context. The settlement, with undisclosed terms, may contain market-entry restrictions relevant to other injectable pharmaceutical manufacturers and formulary planners tracking the US ephedrine market.
PatSnap Eureka searches patents and litigation data to answer instantly.